CULTURE MEDIUM FOR EXPANDING AND CULTURING HUMAN LIVER PROGENITOR CELLS AND APPLICATION THEREOF
20220186181 · 2022-06-16
Assignee
Inventors
- Yinxiong Li (Guangzhou, CN)
- Tingcai Pan (Guangzhou, CN)
- Yan Chen (Guangzhou, CN)
- Yuanqi Zhuang (Guangzhou, CN)
- Fan Yang (Guangzhou, CN)
Cpc classification
C12N2501/119
CHEMISTRY; METALLURGY
C12N2506/45
CHEMISTRY; METALLURGY
C12N2533/90
CHEMISTRY; METALLURGY
C12N2500/90
CHEMISTRY; METALLURGY
A61L27/3895
HUMAN NECESSITIES
C12N2501/16
CHEMISTRY; METALLURGY
C12N5/0672
CHEMISTRY; METALLURGY
C12N2501/41
CHEMISTRY; METALLURGY
C12N2501/155
CHEMISTRY; METALLURGY
International classification
Abstract
Provided are a culture medium for expanding and cultivating human liver progenitor cells and an application thereof. The chemical components of the formula of the described culture medium are clear, no serum is present, and various components thereof cooperate with each other to synergize. The culture medium is used for the long-term expansion and cultivation of liver progenitor cells in vitro and is used for maintaining the dryness thereof, is beneficial in quickly and efficiently obtaining a large number of functional liver cells, and is suitable for clinical hepatocyte transplantation application as well as for the use of hepatocyte reactors in bioartificial livers.
Claims
1. A culture medium for expanding and culturing human hepatoblasts, comprising a liquid basal culture medium, an insulin-transferrin-sodium selenite mixture, a cytokine, a glycogen synthase kinase 3β inhibitor, a Hedgehog signaling pathway activator, and a transforming growth factor β receptor inhibitor.
2. The culture medium according to claim 1, further comprising albumin.
3. The culture medium according to claim 1, wherein the cytokine comprises a bone morphogenetic growth factor, hepatocyte growth factor, and epidermal growth factor; preferably, the bone morphogenetic growth factor comprises BMP2 and/or BMP4; preferably, the bone morphogenetic growth factor has a mass concentration of 1 ng/mL to 50 ng/mL; preferably, the hepatocyte growth factor has a mass concentration of 1 ng/mL to 100 ng/mL; preferably, the epidermal growth factor has a mass concentration of 1 ng/mL to 200 ng/mL.
4. The culture medium according to claim 2, wherein the glycogen synthase kinase 3β inhibitor has a concentration of 10 nM to 100 μM; preferably, the insulin-transferrin-sodium selenite mixture has a volume percent content of 0.1% to 10%; preferably, the transforming growth factor β receptor inhibitor has a molar concentration of 50 nM to 50 μM; preferably, the Hedgehog signaling pathway activator has a molar concentration of 10 nM to 50 μM.
5. The culture medium according to claim 1, wherein the glycogen synthase kinase 3β inhibitor comprises CHIR99021 and/or CHIR98014; preferably, the transforming growth factor β receptor inhibitor comprises any one or a combination of at least two of A8301, SB431542, or E-616452; preferably, the Hedgehog signaling pathway activator comprises SAG and/or Purmorphaminede.
6. A method for expanding and culturing human hepatoblasts in vitro for a long term using the culture medium according to claim 1.
7. The method according to claim 6, comprising the following steps: (1) obtaining Ep-CAM.sup.+/C-kit.sup.− hepatoblasts; and (2) subculturing the cells obtained in step (1) in vitro by using the culture medium; preferably, the hepatoblasts in step (1) are from a source comprising any one or a combination of at least two of human pluripotent stem cells, hepatic stem cells, hepatoblasts, or oval cells; preferably, the hepatoblasts in step (1) are obtained by a method comprising flow cytometry sorting.
8. The method according to claim 6, specifically comprising the following steps: (1) obtaining Ep-CAM.sup.+/C-kit.sup.− hepatoblasts through flow cytometry sorting, wherein the hepatoblasts are from a source comprising any one or a combination of at least two of human pluripotent stem cells, hepatic stem cells, hepatoblasts, or oval cells; and (2) subculturing the cells obtained in step (1) in vitro by using the culture medium.
9. Hepatoblasts obtained by being expanded and cultured by using the culture medium according to claim 1.
10. Use of the hepatoblasts according to claim 9 in preparation of transplanted cells for treating liver diseases, preparation of hepatocytes used in a bioartificial liver reactor, liver tissue engineering or in vitro drug screening for liver diseases.
11. The culture medium according to claim 2, wherein the liquid basal culture medium comprises any one or a combination of at least two of a cell culture medium RMPI1640, a cell culture medium DMEM/F12, a cell culture medium MEM, a cell culture medium DMEM, a cell culture medium IMDM, a cell culture medium 199, or a cell culture medium F10.
12. The culture medium according to claim 2, wherein the albumin comprises human recombinant albumin and/or bovine serum albumin.
13. The culture medium according to claim 2, wherein the albumin has a mass concentration of 5 μg/mL to 500 μg/mL.
Description
BRIEF DESCRIPTION OF DRAWINGS
[0052]
[0053]
[0054]
[0055]
[0056]
[0057]
[0058]
[0059]
[0060]
[0061]
[0062]
[0063]
[0064]
[0065]
[0066]
[0067]
[0068]
[0069]
[0070]
[0071]
[0072]
[0073]
[0074]
[0075]
[0076]
[0077]
[0078]
DETAILED DESCRIPTION
[0079] To further elaborate on the technical means adopted and the effects achieved in the present application, the solutions of the present application are further described below through specific examples in conjunction with drawings, but the present application is not limited to the scope of the examples.
Example 1 Preparation of a Medium
[0080] A basal medium, i.e., RPMI1640 was supplemented with 50 μg/mL of human recombinant albumin and 1% (volume percent content) of an insulin-transferrin-sodium selenite (ITS) mixture.
[0081] HBs expansion culture media were prepared, including the above basal medium and an expansion combination: B.sub.20CEH, AB.sub.20CEH, AB.sub.10CEHS, ACEHS, or ACEH. Letters in the expansion combination have the following meanings: A represents 50 nM to 50 μM of transforming growth factor β (TGF-β) receptor inhibitor A8301; B.sub.10 or B.sub.20 represents 10 ng/mL or 10 ng/mL of a bone morphogenetic growth factor (BMP2 or BMP4), respectively; C represents 10 nM to 10 μM of a glycogen synthase kinase 3β (GSK3β) inhibitor; E represents 1 ng/mL to 200 ng/mL of epidermal growth factor (EGF); H represents 1 ng/mL to 100 ng/mL of hepatocyte growth factor (HGF), and S represents 10 nM to 50 μM of a Hedgehog signaling pathway activator.
[0082] An optimized HBs expansion culture medium was prepared, i.e. including the above basal medium and the expansion combination AB.sub.10CEHS, i.e. including 5 μM of A8301, 20 ng/mL of BMP4, 3 μM of CHIR99021, 20 ng/mL of EGF, 20 ng/mL of HGF, and 0.5 μM of SAG. Cells were digested with Accutase enzyme and subcultured when grown to 80% confluency.
Example 2 Expansion of HBs Obtained Through hPSC Differentiation
[0083] hPSCs (H1 or iPSCs from the Key Laboratory of Stem Cells) were cultured in a 12-well plate coated with 1% Matrigel (a growth factor reduced, BD Bioscience) in culture medium mTeSR1 (Stem Cell Technologies). The culture medium was changed to a culture medium for DE-directed induction when the hPSCs grew at 60%-70% confluency, where RPMI1640 contained 2% of B27 (minus insulin, Invitrogen), 3 μM of CHIR99021 (CHIR) and 100 ng/mL of Activin A. The hPSCs were induced for one day and then induced for another two days with CHIR removed. At this time, the cells differentiated into DE cells. Then, the culture medium was changed to a culture medium for directed differentiation into hepatoblasts, where RPMI1640 contained 2% of B27 (Invitrogen), 20 ng/mL BMP2, 20 ng/mL of BMP4 and 30 ng/mL of FGF4, and the DE cells were induced for four days. The culture medium was then replaced with RPMI1640 that contained 2% of B27, 20 ng/mL of BMP4 and 20 ng/mL of HGF4 and the DE cells were induced for another three says and further differentiated into HBs.
[0084] An induction process of HBs and the identification of cells at each relevant stage are shown in
[0085] hPSCs may be induced to differentiate into HBs which have a strong capability to proliferate. HBs may be expanded in large amounts under suitable culture conditions, and may further rapidly differentiate into functional mature hepatocytes and cholangiocytes. Therefore, large-scale expansion of HBs obtained through inducing hPSCs provides a source for rapid and efficient acquisition of a large number of functional hepatocytes, and thus is an effective method for meeting the requirement for a large number of hepatocytes in clinical hepatocyte transplantation and hepatocyte reactors in bioartificial liver.
[0086] At present, an effective method for long-term culturing and expanding HBs in vitro has not been established in the industry. Difficulties lie in the lack of a deep understanding of the process and regulation mechanism of the differentiation of hPSCs into liver cells and the unclear regulation mechanisms of HB proliferation and sternness maintenance. Therefore, the regulation mechanism during directed differentiation of hPSCs to liver lineage is to be elucidated, the regulation mechanism during HB proliferation and stemness maintenance is to be clarified, and a method for expanding and culturing HBs whose formula has clear chemical components and is serum-free is to be established so that HBs can be expanded and cultured to a large scale, which will facilitate the rapid and efficient acquisition of a large number of functional hepatocytes and the application of HBs to the treatment of liver diseases such as cell transplantation and bioartificial liver dialysis.
[0087] Based on an established method for inducing directed differentiation to liver lineage, signaling pathways related to proliferation and differentiation of HBs are analyzed, the regulation mechanisms of key signaling pathways such as Wnt, TGF-β, BMP, and Hedgehog on HB proliferation and maintenance of liver progenitor characteristics are clarified, and cytokines and small molecule compounds are further adopted to regulate related signaling pathways, so as to develop a formula of a culture medium which supports stable proliferation of HBs and better maintains the liver progenitor characteristics.
[0088] First, during differentiation of hPSCs into HBs, the activity of the signaling pathways related to the proliferation and differentiation of HBs was quantitatively analyzed through RT-PCR. The results showed that the activity of the signaling pathways such as Wnt or Hedgehog related to the proliferation of HBs was down-regulated during the differentiation (
[0089] Further, effects of the signaling pathways on the proliferation and differentiation of HBs were analyzed by regulating the related signaling pathways with small molecules. The results showed that CHIR, A8301 and SAG promoted the proliferation of HBs (
[0090] In addition to proliferation, the effects of the related signaling pathways on the characteristics of HBs were further analyzed. The results showed that CHIR promoted the proliferation of HBs and inhibited the expression of AFP, that is, inhibited the maintenance of the characteristics of HBs. Whereas, A8301 and SAG promoted the expression of liver cell-related genes such as AFP, that is, promoted the maintenance of the characteristics of HBs (
[0091] The above results showed the balance of the regulation of the related signaling pathways such as Wnt, TGF-β, BMP, and Hedgehog on the proliferation and differentiation of HBs (
[0092] Based on this, small molecule compounds were further screened to optimize the formula for the expansion and culture of HBs (
TABLE-US-00001 TABLE 1 Treatment AFP.sup.+ HNF4α.sup.+ B.sub.20CEH 81.8% +/− 4.2 83.4% +/− 4.8 AB.sub.20CEH 94.5% +/− 3.3 96.2% +/− 2.3 AB.sub.10CEHS 96.7% +/− 5.4 98.8% +/− 6.0 ACEHS 77.2% +/− 5.0 86.2% +/− 4.5 ACEH 72.7% +/− 5.2 81.5% +/− 6.5
[0093] The HBs obtained through the differentiation of hPSCs were digested into single cells by Accutase (life), resuspended in PBS containing 3% of BSA, and further incubated with Ep-CAM (Milteny) and C-Kit (BD Biosciences) antibodies. Then, Ep-CAM.sup.+/C-Kit.sup.− HBs were sorted through flow cytometry. The sorted HBs were expanded and cultured in a plate coated with 1% Matrigel in optimized HB expansion medium AB.sub.10CEHS, that is, basal medium RPMI1640 containing 2% of B27 and 1% of ITS (life), containing cytokines: 20 ng/mL of BMP4 and 20 ng/mL of EGF, and small molecule compounds: 20 ng/mL of HGF, 3 μM of CHIR, 5 μM of A8301, and 0.5 μM of SAG. Cells were digested with Accutase and subcultured when grown to 80% confluency.
[0094]
[0095] As shown in
[0096] The above results show that the system and method for expanding and culturing HBs, which are established in the present application, can selectively expand HBs obtained by inducing hPSCs for a long time while maintaining stable HB phenotypes and related functions.
Example 3 HBs being Induced to Differentiate into Functional Mature Hepatocytes and Cholangiocytes
[0097] HBs were grown to 90% confluency under expansion and culture conditions, then the culture medium was changed to a mature hepatocyte induction medium, that is, basal medium HepatoZYME-SFM (Gibco) containing 10 ng/mL of OncostatinM (OSM), 0.1 μM of dexamethasone (DEX; Sigma-Aldrich) and 0.5 mM of NH4Cl (Sigma-Aldrich). The HBs were induced for seven days and differentiated into hepatocyte-like cells.
[0098]
[0099] As shown in
[0100] These results show that the system and method for expanding and culturing HBs, which are established in the present application, can expand HBs for a long term without affecting their capability to differentiate, and the expanded HBs may be rapidly and efficiently induced to differentiate into mature hepatocytes with strong function of mature hepatocytes, such as metabolic detoxification and urea synthesis. The culture medium needs to be changed every day in the above cell culture and induction process.
[0101] Under Matrigel 3D culture conditions, both expanded and unexpanded HBs were differentiated into bile duct structures in a bile duct differentiation medium and expressed cholangiocyte marker proteins such as CK7 and CK19. These results suggest that the expanded HBs have the same dual potential to differentiate into hepatocytes and cholangiocytes as the unexpanded HBs. Unless specially noted, the cytokines used for cell culture and induction were purchased from PeproTech and the small molecule compounds were purchased from Selleck.
Example 4 Transplantation of Expanded HBs to Repair the Liver in Mouse Models of Acute Liver Injury
[0102] Immunodeficient NSI mice were treated with DMN to establish an acute liver injury model. HBs before and after expansion were transplanted into the mouse models of liver injury to verify the proliferation and differentiation of the HBs before and after expansion as well as functions thereof to repair injured liver in vivo.
[0103]
[0104] As shown by experimental results in
[0105] These results show that when transplanted into the liver injury model mice, the HBs expanded and cultured for a long term through the system and method for expanding and culturing HBs, which are established in the present application, can be homed and colonized into injured liver tissues, participate in the repair of liver parenchyma and the reconstruction of bile ducts, effectively recover the function of the injured liver, and save liver injury model animals, just like HBs before expansion. Therefore, the present disclosure will facilitate the rapid and efficient acquisition of a large number of functional hepatocytes and is suitable for use in clinical hepatocyte transplantation and hepatocyte reactors in bioartificial liver.
[0106] To conclude, the present application provides a culture medium for expanding and culturing human hepatoblasts and use thereof. The culture medium is simple and reasonable in formula, clear in chemical composition, and serum-free, have components that cooperate with each other for synergy, and is used for expanding and culturing HBs in vitro for a long term and maintaining the stemness of HBs, conducive to the rapid and efficient acquisition of a large number of functional hepatocytes, and suitable for use in clinical hepatocyte transplantation and hepatocyte reactors in bioartificial liver. The present application will bring hope for the lives of millions of new liver cirrhosis patients at a compensation/decompensation stage and patients with acute hepatotoxicity and has a broad application prospect and a huge market value.
[0107] The applicant has stated that although the detailed method of the present application is described through the examples described above, the present application is not limited to the detailed method described above, which means that implementation of the present application does not necessarily depend on the detailed method described above. It should be apparent to those skilled in the art that any improvements made to the present application, equivalent replacements of raw materials of the product of the present application, additions of adjuvant ingredients to the product of the present application, and selections of specific manners, etc., all fall within the protection scope and the disclosed scope of the present application.